S Lamin1, H S Chew2, S Chavda2, A Thomas2, M Piano3, L Quilici3, G Pero3, M Holtmannspolter4, M E Cronqvist4, A Casasco5, L Guimaraens5, L Paul5, A Gil Garcia5, A Aleu5, R Chapot6. 1. From the Department of Neuroradiology (S.L., H.S.C., S.C., A.T.), University Hospitals Birmingham National Health Service Foundation Trust, Queen Elizabeth Hospital Birmingham, UK Saleh.Lamin@uhb.nhs.uk. 2. From the Department of Neuroradiology (S.L., H.S.C., S.C., A.T.), University Hospitals Birmingham National Health Service Foundation Trust, Queen Elizabeth Hospital Birmingham, UK. 3. Neuroradiologia Department (M.P., L.Q., G.P.), Ospedale Niguarda Ca' Granda, Milan, Italy. 4. Department of Neuroradiology, Section 3023 (M.H., M.E.C.), University of Copenhagen, Rigshospitalet, Copenhagen, Denmark. 5. Instituto de Neurociencias Avanzadas de Madrid (A.C., L.G., L.P., A.G.G., A.A.), Hospital Nuestra Señora del Rosario, Madrid, Spain. 6. Klinik für Radiologie und Neuroradiologie (R.C.), Alfried Krupp Krankenhaus, Essen, Germany.
Abstract
BACKGROUND AND PURPOSE: The introduction of liquid embolic agents has revolutionized endovascular approach to cranial vascular malformations. The aim of the study was to retrospectively assess the efficacy and safety of Precipitating Hydrophobic Injectable Liquid (PHIL), a new nonadhesive liquid embolic agent, in the treatment of patients with cranial dural arteriovenous fistulas. The primary end point was the rate of complete occlusion of dural arteriovenous fistulas. Secondary end points included the incidence of adverse events and clinical status at 3-month follow-up. MATERIALS AND METHODS: This was a retrospective multicenter study. Twenty-six consecutive patients with dural arteriovenous fistulas (de novo or previously treated) treated by injection of PHIL only or with PHIL in combination with other embolization products (such as Onyx or detachable coils) were included in the study. Recruitment started in August 2014 and ended in September 2015. RESULTS: Twenty-two (85%) patients were treated with PHIL only, with 3 patients treated with both PHIL and Onyx, and 1, with both PHIL and coils. Immediate complete angiographic occlusion was achieved in 20 (77%) patients. Of the 6 patients with residual fistulas, 3 were retreated with PHIL and 1 achieved angiographic cure. An adverse event was seen in 1 patient who developed worsening of preexisting ataxia due to acute thrombosis of the draining vein. CONCLUSIONS: PHIL appears to be safe and effective for endovascular treatment of cranial dural arteriovenous fistulas. Short-term angiographic and clinical results are comparable with those of Onyx, with the added advantage of easier preparation and improved homogeneous cast visualization. The use of iodine as a radio-opacifier also produces considerably less artifacts on CT compared with tantalum-based embolic materials.
BACKGROUND AND PURPOSE: The introduction of liquid embolic agents has revolutionized endovascular approach to cranial vascular malformations. The aim of the study was to retrospectively assess the efficacy and safety of Precipitating Hydrophobic Injectable Liquid (PHIL), a new nonadhesive liquid embolic agent, in the treatment of patients with cranial dural arteriovenous fistulas. The primary end point was the rate of complete occlusion of dural arteriovenous fistulas. Secondary end points included the incidence of adverse events and clinical status at 3-month follow-up. MATERIALS AND METHODS: This was a retrospective multicenter study. Twenty-six consecutive patients with dural arteriovenous fistulas (de novo or previously treated) treated by injection of PHIL only or with PHIL in combination with other embolization products (such as Onyx or detachable coils) were included in the study. Recruitment started in August 2014 and ended in September 2015. RESULTS: Twenty-two (85%) patients were treated with PHIL only, with 3 patients treated with both PHIL and Onyx, and 1, with both PHIL and coils. Immediate complete angiographic occlusion was achieved in 20 (77%) patients. Of the 6 patients with residual fistulas, 3 were retreated with PHIL and 1 achieved angiographic cure. An adverse event was seen in 1 patient who developed worsening of preexisting ataxia due to acute thrombosis of the draining vein. CONCLUSIONS: PHIL appears to be safe and effective for endovascular treatment of cranial dural arteriovenous fistulas. Short-term angiographic and clinical results are comparable with those of Onyx, with the added advantage of easier preparation and improved homogeneous cast visualization. The use of iodine as a radio-opacifier also produces considerably less artifacts on CT compared with tantalum-based embolic materials.
Authors: James David Rabinov; Albert J Yoo; Christopher S Ogilvy; Bob S Carter; Joshua A Hirsch Journal: J Neurointerv Surg Date: 2012-05-01 Impact factor: 5.836
Authors: H Duffau; M Lopes; V Janosevic; J P Sichez; T Faillot; L Capelle; M Ismaïl; A Bitar; F Arthuis; D Fohanno Journal: J Neurosurg Date: 1999-01 Impact factor: 5.115
Authors: C Cognard; Y P Gobin; L Pierot; A L Bailly; E Houdart; A Casasco; J Chiras; J J Merland Journal: Radiology Date: 1995-03 Impact factor: 11.105
Authors: Jingjie Hu; Hassan Albadawi; Brian W Chong; Amy R Deipolyi; Rahul A Sheth; Ali Khademhosseini; Rahmi Oklu Journal: Adv Mater Date: 2019-06-06 Impact factor: 30.849
Authors: Edgar A Samaniego; Colin P Derdeyn; Minako Hayakawa; David Hasan; Santiago Ortega-Gutierrez Journal: Interv Neuroradiol Date: 2018-07-04 Impact factor: 1.610
Authors: Dominik F Vollherbst; Ruth Otto; Thuy Do; Hans U Kauczor; Martin Bendszus; Christof M Sommer; Markus A Möhlenbruch Journal: Interv Neuroradiol Date: 2018-07-04 Impact factor: 1.610
Authors: P Bhogal; M AlMatter; V Hellstern; H Bäzner; O Ganslandt; H Henkes; M Aguilar Pérez Journal: Clin Neuroradiol Date: 2018-08-30 Impact factor: 3.649